- Polypeptide Group is expanding its Ambernath facility in India, increasing production capacity by over three times and adding multi-purpose development infrastructure.
- The upgraded site will integrate sustainable practices, support multiple healthcare segments, and create new employment opportunities, with completion expected by the end of 2026.
Polypeptide Group has announced a major investment to expand its Ambernath facility in India, as part of its global growth strategy alongside capacity investments in Malmö and Braine-l’Alleud. The expansion is designed to increase production capacity by more than threefold and enhance development capabilities for complex peptide therapeutics.
The upgraded Ambernath site will feature cutting-edge technology and development infrastructure, supporting a multi-purpose operation that serves several healthcare segments. The facility will also integrate sustainable practices throughout its operations.
The expansion is expected to generate new employment opportunities for local communities, reflecting PolyPeptide’s commitment to both operational growth and social responsibility.
“This investment allows us to diversify our portfolio and strengthen our position as a trusted CDMO partner for complex peptide therapeutics worldwide,” the company stated.
The Ambernath transformation is scheduled for completion by the end of 2026.
